{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T20:55:09Z","timestamp":1770152109941,"version":"3.49.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019306","name":"Chandigarh University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019306","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bbrc.2025.153019","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T15:51:45Z","timestamp":1763653905000},"page":"153019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Current advancements in tubulin targeting agents for breast cancer: Design strategies, structure-activity relationships, and pharmacological insights"],"prefix":"10.1016","volume":"793","author":[{"given":"Jasreen","family":"Uppal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2025.153019_bib1","article-title":"Fighting breast cancer in low-and-middle-income countries\u2013what must we do to get every woman screened on regular basis?","volume":"21","author":"Manson","year":"2023","journal-title":"Sci. Afr."},{"key":"10.1016\/j.bbrc.2025.153019_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"Ca - Cancer J. Clin."},{"key":"10.1016\/j.bbrc.2025.153019_bib3","series-title":"Subtypes of Breast Cancer, Breast Cancer [Internet]","author":"Orrantia-Borunda","year":"2022"},{"key":"10.1016\/j.bbrc.2025.153019_bib4","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.3390\/cells9122644","article-title":"Hormone receptor loss in breast cancer: molecular mechanisms, clinical settings, and therapeutic implications","volume":"9","author":"Zattarin","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bbrc.2025.153019_bib5","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bbrc.2025.153019_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41416-020-01161-4","article-title":"The lingering mysteries of metastatic recurrence in breast cancer","volume":"124","author":"Riggio","year":"2021","journal-title":"British journal of cancer"},{"key":"10.1016\/j.bbrc.2025.153019_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101056","article-title":"Chemotherapeutic drugs: cell death-and resistance-related signaling pathways. Are they really as smart as the tumor cells?","volume":"14","author":"Mollaei","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bbrc.2025.153019_bib8","doi-asserted-by":"crossref","first-page":"7652","DOI":"10.3390\/ijms26157652","article-title":"Microtubule-targeting agents: advances in tubulin binding and small molecule therapy for gliomas and neurodegenerative diseases","volume":"26","author":"Ezzo","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2025.153019_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101511","article-title":"The mechanism of tubulin assembly into microtubules: insights from structural studies","volume":"23","author":"Knossow","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.bbrc.2025.153019_bib10","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s12967-024-05234-3","article-title":"The microtubule targeting agent ST-401 triggers cell death in interphase and prevents the formation of polyploid giant cancer cells","volume":"22","author":"Vicente","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbrc.2025.153019_bib11","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.3390\/cancers13225650","article-title":"Microtubule targeting agents in disease: classic drugs, novel roles","volume":"13","author":"Wordeman","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2025.153019_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105398","article-title":"More is different: reconstituting complexity in microtubule regulation","volume":"299","author":"Lawrence","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2020.151075","article-title":"Microtubule-targeting agents and their impact on cancer treatment","volume":"99","author":"\u010cerm\u00e1k","year":"2020","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.bbrc.2025.153019_bib14","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1002\/mog2.46","article-title":"Microtubule\u2010targeting agents for cancer treatment: seven binding sites and three strategies","volume":"2","author":"Wang","year":"2023","journal-title":"MedComm\u2013Oncology"},{"key":"10.1016\/j.bbrc.2025.153019_bib15","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1021\/ci040123t","article-title":"ChemDraw 8 ultra, windows and macintosh versions","volume":"44","author":"Mendelsohn","year":"2004","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"10.1016\/j.bbrc.2025.153019_bib16","series-title":"Chemdraw Ultra 6.0, Cambridge Soft Corporation","year":"2013"},{"key":"10.1016\/j.bbrc.2025.153019_bib17","series-title":"BIOVIA Discovery Studio Modeling Environment","year":"2017"},{"key":"10.1016\/j.bbrc.2025.153019_bib18","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.jmb.2014.02.005","article-title":"The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization","volume":"426","author":"Prota","year":"2014","journal-title":"Journal of molecular biology"},{"key":"10.1016\/j.bbrc.2025.153019_bib19","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/anie.201307749","article-title":"Structural basis of microtubule stabilization by laulimalide and peloruside A","volume":"53","author":"Prota","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bbrc.2025.153019_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160890","article-title":"Structural basis of microtubule destabilization by potent Auristatin anti-mitotics","volume":"11","author":"Waight","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2025.153019_bib21","first-page":"16976","volume":"117","author":"Debs","year":"2020"},{"key":"10.1016\/j.bbrc.2025.153019_bib22","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.bbrc.2020.11.082","article-title":"High-resolution X-ray structure of three microtubule-stabilizing agents in complex with tubulin provide a rationale for drug design","volume":"534","author":"Xiao","year":"2021","journal-title":"Biochemical and biophysical research communications"},{"key":"10.1016\/j.bbrc.2025.153019_bib23","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3253","article-title":"Microtubule-binding agents: a dynamic field of cancer therapeutics","volume":"9","author":"Dumontet","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2025.153019_bib24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s13205-023-03636-6","article-title":"Vinca alkaloids as a potential cancer therapeutics: recent update and future challenges","volume":"13","author":"Banyal","year":"2023","journal-title":"3 Biotech"},{"key":"10.1016\/j.bbrc.2025.153019_bib25","first-page":"82","article-title":"Resistance to anti-tubulin agents: from vinca alkaloids to epothilones","volume":"2","author":"Krause","year":"2019","journal-title":"Cancer Drug Resistance"},{"key":"10.1016\/j.bbrc.2025.153019_bib26","doi-asserted-by":"crossref","first-page":"794","DOI":"10.30574\/wjarr.2022.16.3.1378","article-title":"Role of vinca alkaloids and their derivatives in cancer therapy","volume":"16","author":"Verma","year":"2022","journal-title":"World Journal of Advanced Research and Reviews"},{"key":"10.1016\/j.bbrc.2025.153019_bib27","doi-asserted-by":"crossref","first-page":"29448","DOI":"10.1021\/acsomega.3c02979","article-title":"Effect of colchicine binding site inhibitors on the tubulin intersubunit interaction","volume":"8","author":"Sargsyan","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.bbrc.2025.153019_bib28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/ph13010008","article-title":"Colchicine-binding site inhibitors from chemistry to clinic: a review","volume":"13","author":"McLoughlin","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bbrc.2025.153019_bib29","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3390\/ph14111119","article-title":"Synthesis and antiproliferative evaluation of 3-chloroazetidin-2-ones with antimitotic activity: heterocyclic bridged analogues of combretastatin a-4","volume":"14","author":"Malebari","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bbrc.2025.153019_bib30","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.84791","article-title":"Structural insight into the stabilization of microtubules by taxanes","volume":"12","author":"Prota","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.bbrc.2025.153019_bib31","series-title":"Mayo Clinic Proceedings","first-page":"533","article-title":"Treatment options for breast cancer resistant to anthracycline and taxane","author":"Moreno-Aspitia","year":"2009"},{"key":"10.1016\/j.bbrc.2025.153019_bib32","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s10549-011-1875-6","article-title":"Beyond taxanes: the next generation of microtubule-targeting agents","volume":"133","author":"Cortes","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bbrc.2025.153019_bib33","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/905091","article-title":"Nanoparticle albumin bound paclitaxel in the treatment of human cancer: nanodelivery reaches prime\u2010time?","volume":"2013","author":"Cucinotto","year":"2013","journal-title":"Journal of Drug Delivery"},{"key":"10.1016\/j.bbrc.2025.153019_bib34","first-page":"69","article-title":"Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer","author":"Cobham","year":"2009","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.bbrc.2025.153019_bib35","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3816\/CBC.2008.n.058","article-title":"Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes","volume":"8","author":"Yardley","year":"2008","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.bbrc.2025.153019_bib36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.canlet.2015.06.001","article-title":"\u03b2I-tubulin mutations in the laulimalide\/peloruside binding site mediate drug sensitivity by altering drug\u2013tubulin interactions and microtubule stability","volume":"365","author":"Kanakkanthara","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2025.153019_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107076","article-title":"Tubulin inhibitors. Selected scaffolds and main trends in the design of novel anticancer and antiparasitic agents","volume":"143","author":"Podolak","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188777","article-title":"Combination of microtubule targeting agents with other antineoplastics for cancer treatment","volume":"1877","author":"Liang","year":"2022","journal-title":"Biochimica et Biophysica Acta (BBA)-Reviews on Cancer"},{"key":"10.1016\/j.bbrc.2025.153019_bib39","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.3390\/ijms25063536","article-title":"Noscapine and apoptosis in breast and other cancers","volume":"25","author":"Calaf","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2025.153019_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117091","article-title":"In silico inspired design of urea noscapine congeners as anticancer agents: chemical synthesis and experimental evaluation using breast cancer cells and a xenograft mouse model","volume":"282","author":"Pragyandipta","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117314","article-title":"Discovery of novel thienopyridine indole derivatives as inhibitors of tubulin polymerization targeting the colchicine-binding site with potent anticancer activities","volume":"286","author":"Liu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117139","article-title":"Design, synthesis, and antitumor evaluation of quinazoline-4-tetrahydroquinoline chemotypes as novel tubulin polymerization inhibitors targeting the colchicine site","volume":"283","author":"Lai","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib43","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.3390\/pharmaceutics15122728","article-title":"Podophyllotoxin: recent advances in the development of hybridization strategies to enhance its antitumoral profile","volume":"15","author":"Miranda-Vera","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbrc.2025.153019_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109132","article-title":"Design, synthesis and biological activity of tubulin inhibitors based on the structure of deoxypodophyllotoxin","author":"Zhang","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108355","article-title":"Identification of selenium-containing benzamides as potent microtubule-targeting antitumor agents","volume":"159","author":"Jiang","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib46","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.3390\/molecules29112668","article-title":"Imidazopyridine family: versatile and promising heterocyclic skeletons for different applications","volume":"29","author":"Volpi","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.bbrc.2025.153019_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118242","article-title":"An N-linked imidazo [1, 2-a] pyridine benzoheterobicyclic hybrid inhibits mitosis and cancer cell proliferation by targeting tubulin","author":"Sarkar","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115794","article-title":"Synthesis and biological evaluation of structurally diverse 6-aryl-3-aroyl-indole analogues as inhibitors of tubulin polymerization","volume":"263","author":"Ren","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117981","article-title":"Design, synthesis and biological evaluation of 2-Phenyl indole analogues of OXi8006 as colchicine site inhibitors of tubulin polymerization and vascular disrupting agents","volume":"118","author":"Vairin","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib50","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.3390\/ijms21165712","article-title":"Cinnamic acid derivatives and their biological efficacy","volume":"21","author":"Ruwizhi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2025.153019_bib51","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/B978-0-443-23754-6.00016-1","article-title":"Anticancer activities of coumarins and their structure\u2013activity relationships","volume":"85","author":"Taban","year":"2025","journal-title":"Stud. Nat. Prod. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib52","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1039\/D5MD00484E","article-title":"Multi-Targeted Azacoumarin\u2013Cyanocinnamate Hybrids Induce G2\/M Arrest and Apoptosis via Tubulin, and COX-2\/VEGFR Modulation: insights from in vitro mechanistic basis and in vivo validation","volume":"16","author":"El-Zend","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib53","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1039\/D5MD00406C","article-title":"Microwave-assisted synthesis of tubulin assembly inhibitors as anticancer agents by aryl ring reversal and conjunctive approach","volume":"16","author":"Masci","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib54","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1039\/D4MD00541D","article-title":"Synthesis and evaluation of tetrahydropyrrolo [1, 2-a] quinolin-1 (2 H)-ones as new tubulin polymerization inhibitors","volume":"16","author":"Anisimov","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib55","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/biom15020210","article-title":"Quinazolinones as potential anticancer agents: synthesis and action mechanisms","volume":"15","author":"Deng","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbrc.2025.153019_bib56","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1039\/D4MD00755G","article-title":"Synthesis and screening of novel 2, 4-bis substituted quinazolines as tubulin polymerization promoters and antiproliferative agents","volume":"16","author":"Dwivedi","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib57","doi-asserted-by":"crossref","first-page":"21962","DOI":"10.1039\/D4RA09000D","article-title":"Design, synthesis, in silico and in vitro evaluation of pyrrole\u2013indole hybrids as dual tubulin and aromatase inhibitors with potent anticancer activities","volume":"15","author":"Saruengkhanphasit","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.bbrc.2025.153019_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.140462","article-title":"Development of pyrazolo [1, 5-a] pyrimidine-grafted coumarins as selective carbonic anhydrase inhibitors and tubulin polymerization inhibitors with potent anticancer activity","volume":"303","author":"Elkotamy","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bbrc.2025.153019_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117486","article-title":"Aromatic nitroolefin with inhibition efficacy in triple-negative breast cancer cells by dual targeting RXR\u03b1 and tubulins","volume":"289","author":"Qu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.prmcm.2022.100059","article-title":"Research advances of erianin: source, production, biological activities and pharmacological properties","volume":"2","author":"Qiao","year":"2022","journal-title":"Pharmacological Research-Modern Chinese Medicine"},{"key":"10.1016\/j.bbrc.2025.153019_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117879","article-title":"Discovery of novel 1, 2, 3-triazole arylamide derivatives bearing dithiocarbamate moiety as dual inhibitors of tubulin and LSD1 with potent anticancer activity","author":"Ji","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103486","article-title":"Synthesis and biological evaluation of novel millepachine derivative containing aminophosphonate ester species as novel anti-tubulin agents","volume":"94","author":"Huang","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib63","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bbrc.2023.09.044","article-title":"A review on Millepachine and its derivatives as potential multitarget anticancer agents","volume":"681","author":"Rampogu","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2025.153019_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117249","article-title":"Discovery of novel dual tubulin and MMPs inhibitors for the treatment of lung cancer and overcoming drug resistance","volume":"285","author":"Li","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117058","article-title":"Synthesis, biological evaluation and mechanism study of a novel indole-pyridine chalcone derivative as antiproliferative agent against tumor cells through dual targeting tubulin and HK2","volume":"282","author":"Zheng","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib66","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.3390\/molecules26092708","article-title":"Functional pyrazolo [1, 5-a] pyrimidines: current approaches in synthetic transformations and uses as an antitumor scaffold","volume":"26","author":"Arias-G\u00f3mez","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bbrc.2025.153019_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108792","article-title":"Discovery of pyrazolo [1, 5-a] pyrimidines: synthesis, in silico insights, and anticancer activity via novel CDK2\/tubulin dual inhibition approach","author":"Elgiushy","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108728","article-title":"Novel 3, 4-diaminothieno [2, 3-b] thiophene-2, 5-dicarbohydrazide-based scaffolds as EGFRWT, EGFRT790M, and tubulin polymerization inhibitors with anti-proliferative activity","author":"Aboelez","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib69","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12964-022-00838-y","article-title":"Cancer combination therapies by angiogenesis inhibitors; a comprehensive review","volume":"20","author":"Ansari","year":"2022","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.bbrc.2025.153019_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108713","article-title":"Discovery of novel flavonoid derivatives targeting VEGFR2 and tubulin with potent anticancer efficacy","author":"He","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108334","article-title":"Design and development of new substituted pyrimidine hybrids with imidazole and triazole: exploring utility as an anticancer agent via human topoisomerase-II and tubulin inhibition","volume":"158","author":"Yadav","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108784","article-title":"Design, synthesis and biological evaluation of spirocyclopropyl oxindole-piperazine\/morpholine-based carboxamides as potential anticancer agents","author":"Dastari","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib73","doi-asserted-by":"crossref","first-page":"20495","DOI":"10.1039\/D5RA01257K","volume":"15","author":"Seliem","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.bbrc.2025.153019_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108694","article-title":"Synthesis and apoptotic induction of sulfonamide-based chalcone hybrids as first-in-class dual histone deacetylase-carbonic anhydrase inhibitors with potential anti-tubulin activity","author":"Mohamed","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108853","article-title":"Further insights into the multitarget anticancer activity of tetrahydrocarbazole-1-amine\/5-arylidene-4-thiazolinone based hybrids","author":"Ali","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbrc.2025.153019_bib76","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1039\/D4RA07810A","article-title":"Design, synthesis, molecular docking and anticancer activity of benzothiazolecarbohydrazide\u2013sulfonate conjugates: insights into ROS-induced DNA damage and tubulin polymerization inhibition","volume":"15","author":"Altwaijry","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.bbrc.2025.153019_bib77","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3390\/ph18010118","article-title":"(E)-1-(3-(3-Hydroxy-4-Methoxyphenyl)-1-(3, 4, 5-Trimethoxyphenyl) allyl)-1 H-1, 2, 4-Triazole and related compounds: their synthesis and biological evaluation as novel antimitotic agents targeting breast cancer","volume":"18","author":"Ana","year":"2025","journal-title":"Pharmaceuticals"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25017358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25017358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:14:52Z","timestamp":1766103292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X25017358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":77,"alternative-id":["S0006291X25017358"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.153019","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current advancements in tubulin targeting agents for breast cancer: Design strategies, structure-activity relationships, and pharmacological insights","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.153019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"153019"}}